Our pipeline is led by tazemetostat, an internally developed, orally administered, first-in-class small molecule EZH2 inhibitor, for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. We are currently conducting a comprehensive development program for tazemetostat designed to identify efficient and accelerated pathways to treat as many patients as may benefit.
We are investigating tazemetostat as a single-agent therapy in multiple clinical trials, including Phase 2 clinical trials in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), adult patients with certain genetically defined solid tumors, including INI1-negative tumors and synovial sarcoma, and patients with mesothelioma characterized by BAP loss of function. We are also conducting a clinical trial of tazemetostat in pediatric patients with certain genetically defined solid tumors, including INI1-negative tumors and synovial sarcoma.
Tazemetostat is also being evaluated in combinations and in additional indications, including:
- a combination study of tazemetostat with rituximab in patients with relapsed and/or refractory FL;
- a combination study of tazemetostat with R-CHOP in front-line patients in collaboration with the Lymphoma Study Association;
- a combination study of tazemetostat with the standards of care in patients with castration-resistant prostate cancer, and
- a combination study of tazemetostat with a PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer and ovarian cancer.
Epizyme holds global development and commercialization rights to tazemetostat ex-Japan. Eisai owns development and commercialization rights to tazemetostat in Japan, and a right of first negotiation to rights in the rest of Asia.